Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnostic Potential

The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer

NCT06477055 ·Status: RECRUITING

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

NCT05785208 ·Status: RECRUITING ·Phase: PHASE4

A Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Solid Tumors

NCT05784597 ·Status: COMPLETED ·Phase: PHASE1

NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

NCT03764917 ·Status: UNKNOWN

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT00517790 ·Status: COMPLETED ·Phase: PHASE2

Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection

NCT00831454 ·Status: COMPLETED

An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors

NCT02616211 ·Status: COMPLETED

Prospective Study on Resistance-associated Mutations in Metastatic Lung Cancer

NCT06081270 ·Status: RECRUITING

Glycoprotein in Immunotherapy Response and Efficacy Prediction of Lung Cancer

NCT06730503 ·Status: RECRUITING

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

NCT04811001 ·Status: UNKNOWN ·Phase: PHASE2

Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer

NCT02169349 ·Status: COMPLETED

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

NCT05218759 ·Status: NOT_YET_RECRUITING ·Phase: NA

Study for Patients With Lung Metastatic Advanced Gastric Cancer and NSCLC Treated With Apatinib

NCT03629691 ·Status: COMPLETED

A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.

NCT06854939 ·Status: NOT_YET_RECRUITING

Overcoming Resistance to EGFR Neutralization by Combination of Monoclonal Antibodies and Novel Cancer Drugs

NCT06863818 ·Status: ACTIVE_NOT_RECRUITING

Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)

NCT02293733 ·Status: COMPLETED

R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer

NCT00005989 ·Status: COMPLETED ·Phase: PHASE2

Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer

NCT00579683 ·Status: COMPLETED

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

NCT05458726 ·Status: UNKNOWN ·Phase: PHASE2

NGS-based Large-panel in Targeted Drug Delivery and Immunotherapy of Lung Cancer

NCT04159337 ·Status: UNKNOWN

Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

NCT00989690 ·Status: UNKNOWN ·Phase: PHASE3

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

NCT05104281 ·Status: UNKNOWN ·Phase: PHASE3

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

NCT02906163 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy

NCT04670107 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Development of a Model to Predict Progression-Free Survival After Erlotinib in Patients With Non-Small Cell Lung Cancer

NCT00897533 ·Status: COMPLETED